1
|
Vogelstein B and Kinzler KW: Cancer genes
and the pathways they control. Nat Med. 10:789–799. 2004.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
3
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
4
|
Zhang S, Cui Y, Weng Z, Gong X, Chen M and
Zhong B: Changes on the disease pattern of primary colorectal
cancers in Southern China: a retrospective study of 20 years. Int J
Colorectal Dis. 24:943–949. 2009.PubMed/NCBI
|
5
|
Petrova TV, Nykänen A, Norrmén C, et al:
Transcription factor PROX1 induces colon cancer progression by
promoting the transition from benign to highly dysplastic
phenotype. Cancer Cell. 13:407–419. 2008. View Article : Google Scholar : PubMed/NCBI
|
6
|
Sansom OJ, Meniel VS, Muncan V, et al:
Myc deletion rescues Apc deficiency in the small intestine.
Nature. 446:676–679. 2007. View Article : Google Scholar
|
7
|
Micel LN, Tentler JJ, Smith PG and
Eckhardt GS: Role of ubiquitin ligases and the proteasome in
oncogenesis: novel targets for anticancer therapies. J Clin Oncol.
31:1231–1238. 2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Bedford L, Lowe J, Dick LR, Mayer RJ and
Brownell JE: Ubiquitin-like protein conjugation and the
ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov.
10:29–46. 2011. View
Article : Google Scholar : PubMed/NCBI
|
9
|
Reinstein E and Ciechanover A: Narrative
review: protein degradation and human diseases: the ubiquitin
connection. Ann Intern Med. 145:676–684. 2006. View Article : Google Scholar : PubMed/NCBI
|
10
|
Naujokat C and Sarić T: Concise review:
role and function of the ubiquitin-proteasome system in mammalian
stem and progenitor cells. Stem Cells. 25:2408–2418. 2007.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Bronner C, Achour M, Arima Y, Chataigneau
T, Saya H and Schini-Kerth VB: The UHRF family: oncogenes that are
drugable targets for cancer therapy in the near future? Pharmacol
Ther. 115:419–434. 2007. View Article : Google Scholar : PubMed/NCBI
|
12
|
Hopfner R, Mousli M, Jeltsch JM, et al:
ICBP90, a novel human CCAAT binding protein, involved in the
regulation of topoisomerase IIα expression. Cancer Res. 60:121–128.
2000.
|
13
|
Mori T, Li Y, Hata H, Ono K and Kochi H:
NIRF, a novel RING finger protein, is involved in cell-cycle
regulation. Biochem Biophys Res Commun. 296:530–536. 2002.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Kotliarov Y, Steed ME, Christopher N, et
al: High-resolution global genomic survey of 178 gliomas reveals
novel regions of copy number alteration and allelic imbalances.
Cancer Res. 66:9428–9436. 2006. View Article : Google Scholar : PubMed/NCBI
|
15
|
Wu J, Liu S, Liu G, et al: Identification
and functional analysis of 9p24 amplified genes in human breast
cancer. Oncogene. 31:333–341. 2012. View Article : Google Scholar : PubMed/NCBI
|
16
|
Li DW, Tang HM, Fan JW, et al: Expression
level of Bmi-1 oncoprotein is associated with progression and
prognosis in colon cancer. J Cancer Res Clin Oncol. 136:997–1006.
2010. View Article : Google Scholar : PubMed/NCBI
|
17
|
Yan DW, Fan JW, Yu ZH, et al:
Downregulation of metallothionein 1F, a putative oncosuppressor, by
loss of heterozygosity in colon cancer tissue. Biochim Biophys
Acta. 1822:918–926. 2012. View Article : Google Scholar : PubMed/NCBI
|
18
|
Troup S, Njue C, Kliewer EV, et al:
Reduced expression of the small leucine-rich proteoglycans,
lumican, and decorin is associated with poor outcome in
node-negative invasive breast cancer. Clin Cancer Res. 9:207–214.
2003.PubMed/NCBI
|
19
|
Bachmann IM, Puntervoll HE, Otte AP and
Akslen LA: Loss of BMI-1 expression is associated with clinical
progress of malignant melanoma. Mod Pathol. 21:583–590. 2008.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Hashimoto Y, Skacel M, Lavery IC,
Mukherjee AL, Casey G and Adams JC: Prognostic significance of
fascin expression in advanced colorectal cancer: an
immunohistochemical study of colorectal adenomas and
adenocarcinomas. BMC Cancer. 6:2412006. View Article : Google Scholar : PubMed/NCBI
|
21
|
Lorenzato M, Caudroy S, Bronner C, et al:
Cell cycle and/or proliferation markers: what is the best method to
discriminate cervical high-grade lesions? Hum Patho. 36:1101–1107.
2005. View Article : Google Scholar : PubMed/NCBI
|
22
|
Crnogorac-Jurcevic T, Gangeswaran R,
Bhakta V, et al: Proteomic analysis of chronic pancreatitis and
pancreatic adenocarcinoma. Gastroenterology. 129:1454–1463. 2005.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Unoki M, Kelly JD, Neal DE, Ponder BA,
Nakamura Y and Hamamoto R: UHRF1 is a novel molecular marker for
diagnosis and the prognosis of bladder cancer. Br J Cancer.
101:98–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
24
|
Wu TF, Zhang W, Su ZP, et al: UHRF2 mRNA
expression is low in malignant glioma but silencing inhibits the
growth of U251 glioma cells in vitro. Asian Pac J Cancer Prev.
13:5137–5142. 2012. View Article : Google Scholar : PubMed/NCBI
|
25
|
Sun Y: E3 ubiquitin ligases as cancer
targets and biomarkers. Neoplasia. 8:645–654. 2006. View Article : Google Scholar : PubMed/NCBI
|
26
|
Ma C, Rong Y, Radiloff DR, et al:
Extracellular matrix protein βig-h3/TGFBI promotes metastasis of
colon cancer by enhancing cell extravasation. Genes Dev.
22:308–321. 2008.
|